La Jolla Pharmaceutical Co., of San Diego, reported that for the three months ended March 31, Giapreza, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock, had net product sales of $4.4 million, compared to $800,000 for the same period in 2018.